Despite the latter, while IL-17 A immunomodulation has been used effectively in the treatment of certain Type 17-driven inflammatory conditions [8], the two trials of anti-IL-17 A therapies published so far have not proven utility in treating patients with moderate-to-severe asthma, possibly due to the lack of stratification of specific immunological endotypes [9, 10]. This evidence concerns the gene IL17A and asthma.